[1]莫春艳,张学东.原发性眼内淋巴瘤的诊断及治疗[J].眼科新进展,2017,37(6):597-600.[doi:10.13389/j.cnki.rao.2017.0152]
　MO Chun-Yan,ZHANG Xue-Dong.Diagnosis and treatment of primary intraocular lymphoma[J].Recent Advances in Ophthalmology,2017,37(6):597-600.[doi:10.13389/j.cnki.rao.2017.0152]
点击复制

原发性眼内淋巴瘤的诊断及治疗/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
37卷
期数:
2017年6期
页码:
597-600
栏目:
文献综述
出版日期:
2017-06-05

文章信息/Info

Title:
Diagnosis and treatment of primary intraocular lymphoma
作者:
莫春艳; 张学东
400016　重庆市，重庆医科大学附属第一医院眼科 重庆市眼科研究所 眼科学重庆市市级重点实验室
Author(s):
MO Chun-Yan; ZHANG Xue-Dong
Department of Ophthalmology，the First Affiliated Hospital of Chongqing Medical University，Chongqing Key Laboratory of Ophthalmology，Chongqing Eye Institute，Chongqing 400016，China
关键词:
原发性眼内淋巴瘤; 诊断; 治疗
Keywords:
primary intraocular lymphoma; diagnosis; treatment
分类号:
R774.1
DOI:
10.13389/j.cnki.rao.2017.0152
文献标志码:
A
摘要:
原发性眼内淋巴瘤（primary intraocular lymphoma，PIOL）多为弥漫大B细胞淋巴瘤，易被误诊为葡萄膜炎。其恶性程度高，预后差，因此早期诊断并治疗至关重要。PIOL主要检测方法包括细胞学分析、细胞因子检测、免疫细胞化学分析、基因检测等，多种检测方式联合可以提高PIOL确诊率，但眼内组织活检是诊断PIOL的金标准。PIOL治疗尚无统一方案，目前主要以眼内局部化学治疗及眼眶放射治疗为主，多种治疗方法联合可以提高难治性PIOL的疗效。基于此，本文旨在通过综述目前PIOL的诊断及治疗，为临床诊疗提供一定的参考。
Abstract:
Primary intraocular lymphoma (PIOL) is mostly composed by diffuse large B-cell lymphoma with a high degree of malignancy and often masquerades as uveitis.Moreover，it has a poor prognosis，therefore the early diagnosis and treatment are very important.Cytology，cytokine analysis，immunohistochemistry and genetic testing are often used in combination to improve the diagnosis rate of PIOL，however，eye tissue biopsy is the gold standard for diagnosis of PIOL.Currently，since there is no unified treatment program，the main treatment is given priority to local chemotherapy and orbital radiotherapy，and the use of multiple therapies can improve the efficacy of refractory PIOL.Base on these，this article reviews the current diagnosis and treatment for providing certain reference.

参考文献/References:

［1］　COUPLAND SE，CHAN CC，SMITH J.Pathophysiology of retinal lymphoma［J］.Ocul Immunol Inflamm，2009，17（4）：227-237.
［2］　JAHNKE K，KORFEL A，KOMM J，BECHRAKIS NE，STEIN H，THIEL E，et al.Intraocular lymphoma 2000-2005：results of a retrospective multicentre trial［J］.Graefes Arch Clin Exp Ophthalmol，2006，244（6）：663-669.
［3］　GRIMM SA，MCCANNEL CA，OMURO AM，FERRERI AJ，BLAY JY，NEUWELT EA，et al.Primary CNS lymphoma with intraocular involvement：international PCNSL collaborative group report［J］.Neurology，2008，71（17）：1355-1360.
［4］　MOCHIZUKI M，SINGH AD.Epidemiology and clinical features of intraocular lymphoma［J］.Ocul Immunol Inflamm，2009，17（2）：69-72.
［5］　CHAN CC，RUBENSTEIN JL，COUPLAND SE，DAVIS JL，HARBOUR JW，JOHNSTON PB，et al.Primary vitreoretinal lymphoma：a report from an international primary central nervous system lymphoma collaborative group symposium［J］.Oncologist，2011，16（11）：1589-1599.
［6］　CHAN CC，HAEN SP，MHLE R，ZIERHUT M.Primary Intraocular Lymphoma［M］.Springer-Verlag，Berlin Heidelberg，2016：1467-1485.
［7］　PAULUS W.Classification，pathogenesis and molecular pathology of primary CNS lymphomas［J］.J Neurooncol，1999，43（3）：203-208.
［8］　RAJA H，SALOMAO DR，VISWANATHA DS，PULIDO JS.Prevalence of myd88 l265p mutation in histologically proven，diffuse large b-cell vitreoretinal lymphoma［J］.Retina，2016，36（3）：624-628.
［9］　FISCHER L，KORFEL A，PFEIFFER S，KIEWE P，VOLK HD，CAKIROGLU H，et al.CXCL13 and CXCL12 in central nervous system lymphoma patients［J］.Clin Cancer Res，2009，15（19）：5968-5973.
［10］　CHAN CC.Molecular pathology of primary intraocular lymphoma［J］.Trans Am Ophthalmol Soc，2003，101：275-292.
［11］　KIM YK，KIM HJ，WOO KI，KIM YD.Intraocular lymphoma after cardiac transplantation：magnetic resonance imaging findings［J］.Korean J Radiol，2013，14（1）：122-125.
［12］　HWANG CS，YEH S，BERGSTROM CS.Diagnostic vitrectomy for primary intraocular lymphoma：when，why，how［J］?Int Ophthalmol Clin，2014，54（2）：155-171.
［13］　CHAN CC，SEN HN.Current concepts in diagnosing and managing primary vitreoretinal （intraocular） lymphoma［J］.Discov Med，2013，15（81）：93-100.
［14］　KIMURA K，USUI Y，GOTO H.Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma［J］.Jpn J Ophthalmol，2012，56（4）：383-389.
［15］　WITMER MT.Primary vitreoretinal lymphoma：management of isolated ocular disease［J］.Cancer Control，2016，23（2）：110-116.
［16］　CASADY M，FAIA L，NAZEMZADEH M，NUSSENBLATT R，CHAN CC，SEN HN，et al.Fundus autofluorescence patterns in primary intraocular lymphoma［J］.Retina，2014，34（2）：366-372.
［17］　FARDEAU C，LEE CP，MERLE-BERAL H，CASSOUX N，BODAGHI B，DAVI F，et al.Retinal fluorescein，indocyanine green angiography，and optic coherence tomography in non-Hodgkin primary intraocular lymphoma［J］.Am J Ophthalmol，2009，147（5）：886-894.
［18］　SAITO T，OHGURO N，IWAHASHI C，HASHIDA N.Optical coherence tomography manifestations of primary vitreoretinal lymphoma［J］.Graefes Arch Clin Exp Ophthalmol，2016，254（12）：2319-2326.
［19］　RODRIGUEZ EF，SEPAH YJ，JANG HS，IBRAHIMM，NGUYEN QD，RODRIGUEZ FJ.Cytologic features in vitreous preparations of patients with suspicion of intraocular lymphoma［J］.Diagn Cytopathol，2014，42（1）：37-44.
［20］　HORMIGO A，ABREY L，HEINEMANN MH，DEANGELIS LM.Ocular presentation of primary central nervous system lymphoma：diagnosis and treatment［J］.Br J Haematol，2004，126（2）：202-208.
［21］　KIMURA K，USUI Y，GOTO H.Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma［J］.Jpn J Ophthalmol，2012，56（4）：383-389.
［22］　BAEHRING JM，ANDROUDI S，LONGTINE JJ，BETENSKY RA，SKLAR J，FOSTER CS，et al.Analysis of clonal immunoglobulin heavy chain rearrangements in ocular lymphoma［J］.Cancer，2005，104（3）：591-597.
［23］　GONZALES JA，CHAN CC.Biopsy techniques and yields in diagnosing primary intraocular lymphoma［J］.Int J Ophthalmol，2007，27（4）：241-250.
［24］　COSTOPOULOS M，TOUITOU V，GOLMARD JL，DARUGARA，FISSON S，BONNEMYEP，et al.ISOLD：A new highly sensitive interleukin score for intraocular lymphoma diagnosis［J］.Ophthalmology，2016，123（7）：1626-1628.
［25］　BONZHEIM I，GIESE S，DEUTER C，ZIERHUT M，WAIZEL M，SZURMAN P.et al.High frequency of myd88 mutations in vitreoretinal b-cell lymphoma：a valuable tool to improve diagnostic yield of vitreous aspirates［J］.Blood，2015，126（1），76-79.
［26］　PULIDO JS，SALOMAO DR，FREDERICK LA.VISWANATHA DS.Myd-88 L265p mutations are present in some cases of vitreoretinal lymphoma［J］.Retina，2015，35（4），624-627.
［27］　HOANG-XUAN K，BESSELL E，BROMBERG J，HOTTINGER AF，PREUSSER M，RUDA R，et al.Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients：guidelines from the European Association for Neuro-Oncology［J］.Lancet Oncol，2015，16（7）：e322-e332.
［28］　BERENBOM A，DAVILA RM，LIN HS，HARBOUR JW.Treatment outcomes for primary intraocular lymphoma：implications for external beam radiotherapy［J］.Eye，2007，21（9）：1198-1201.
［29］　TECKIE S，YAHALOM J.Primary intraocular lymphoma：treatment outcomes with ocular radiation therapy alone［J］.Leuk Lymphoma，2014，55（4）：795-801.
［30］　MILGROM SA，CHEAH CY，PINNIX CC，SMITH GL，DABAJA BS，HORACE P，et al.Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma［J］.Leuk Lymphoma，2016，96（2）：1-7.
［31］　ISOBE K，EJIMA Y，TOKUMARU S，SHIKAMA N，SUZUKI G，TAKEMOTO M，et al.Treatment of primary intraocular lymphoma with radiation therapy：a multi-institutional survey in Japan［J］.Leuk Lymphoma，2006，47（9）：1800-1805.
［32］　CITTERIO G，RENI M，FERRERI AJ.Present and future treatment options for primary CNS lymphoma［J］.Expert Opin Pharmacother，2015，16（17）：2569-2579.
［33］　FRENKEL S，HENDLER K，SIEGAL T，SHALOM E，PE’ER J.Intravitreal methotrexate for treating vitreoretinal lymphoma：10 years of experience［J］.Br J Ophthalmol，2008，92（3）：383-388.
［34］　SMITH JR，ROSENBAUM JT，WILSON DJ，DOOLITTLE ND，SIEGAL T，NEUWELT EA，et al.Role of intravitreal methotrexate in the management of prmary central nervous system lymphoma with ocular involvement［J］.Ophthalmology，2002，109（9）：1709-1716.
［35］　BATCHELOR TT，KOLAK G，CIORDIA R，FOSTER CS，HENSON JW.High-dose methotrexate for intraocular lymphoma［J］.Clin Cancer Res，2003，9（2）：711-715.
［36］　MA WL，HOU HA，HSU YJ，CHEN YK，TANG JL，TSAY W，et al.Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection［J］.Ann Hematol，2016，95（4）：593-601.
［37］　JAGLOWSKI SM，ALINARI L，LAPALOMBELLA R，MUTHUSAMY N，BYRD JC.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia［J］.Blood，2010，116（19）：3705-3714.
［38］　KIM H，CSAKY KG，CHAN CC，BUNGAY PM，LUTZ RJ，DEDRICK RL，et al.The pharmacokinetics of rituximab following an intravitreal injection［J］.Exp Eye Res，2006，82（5）：760-766.
［39］　LARKIN KL，SABOO US，COMER GM，FOROOGHIAN F，MACKENSEN F，MERRILL P，et al.Use of intravitreal rituximab for treatment of vitreoretinal lymphoma［J］.Br J Ophthalmol，2014，98（1）：99-103.
［40］　KITZMANN AS，PULIDO JS，MOHNEY BG，BARATZ KH，GRUBE T，MARLER RJ，et al.Intraocular use of rituximab［J］.Eye，2007，21（12）：1524-1527.
［41］　HASHIDA N，OHGURO N，NISHIDA K.Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma［J］.Transl Vis Sci Technol，2012，1（3）：1-11.
［42］　RENI M，ZAJA F，MASON W，PERRY J，MAZZA E，SPINA M，et al.Temozolomide as salvage treatment in primary brain lymphomas［J］.Br J Cancer，2007，96（6）：864-867.
［43］　CHEAH CY，MILGROM S，CHIHARA D，GOMBOS DS，PINNIX CC，DABAJA BS，et al.Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma［J］.Neuro Oncol，2016，18（4）：575-581.
［44］　SOUSSAIN C，CHOQUET S，FOURME E，DELGADILLO D，BOUABDALLAH K，GHESQUIERES H，et al.Intensive chemotherapy with thiotepa，busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma：a retrospective study of 79 cases［J］.Haematologica，2012，97（11）：1751-1756.
［45］　MANNA S，AUGSBURGER JJ，CORREA ZM，LANDERO JA，BANERJEE RK.Development of chitosan and polylactic acid based methotrexate intravitreal micro-implants to treat primary intraocular lymphoma：an in vitro study［J］.J Biomech Eng，2014，136（2）：21018.
［46］　GRIMM SA，PULIDO JS，JAHNKE K，SCHIFF D，HALL AJ，SHENKIER TN，et al.Primary intraocular lymphoma：an international primary central nervous system lymphoma collaborative group report［J］.Ann Oncol，2007，18（11）：1851-1855.
［47］　FERRERI AJ.Who is who in primary vitreoretinal lymphoma［J］？JAMA Oncol，2015，1（7）：977-978.
［48］　PE’ER J，HOCHBERG FH，FOSTER CS.Clinical review：treatment of vitreoretinal lymphoma［J］.Ocul Immunol Inflamm，2009，17（5）：299-306.

相似文献/References:

[1]杨红 阴正勤.眼球震颤的诊断与治疗研究进展[J].眼科新进展,2012,32(5):000.
[2]史大领 王殿强.棘阿米巴性角膜炎的临床特点及诊断[J].眼科新进展,2013,33(6):000.
[3]阎慧,赵少贞.干眼症临床检查的新进展[J].眼科新进展,2008,28(9):000.
[4]陈 彧 赵建民 王夏红 何文龙 张慧敏.视神经脊髓炎的视觉诱发电位和MRI对照研究[J].眼科新进展,2008,28(9):000.
[5]孙飒,张俊杰.抑郁症与干眼关系研究进展[J].眼科新进展,2016,36(11):1090.[doi:10.13389/j.cnki.rao.2016.0291]
　SUN Sa,ZHANG Jun-Ji.Research advances in relationship between depression and dry eye[J].Recent Advances in Ophthalmology,2016,36(6):1090.[doi:10.13389/j.cnki.rao.2016.0291]
[6]王镇,谭晓俊,程钧,等.药物性角膜炎的研究进展[J].眼科新进展,2017,37(2):192.[doi:10.13389/j.cnki.rao.2017.0050]
　WANG Zhen,TAN Xiao-Jun,CHENG Jun,et al.Research advances in toxic keratopathy[J].Recent Advances in Ophthalmology,2017,37(6):192.[doi:10.13389/j.cnki.rao.2017.0050]
[7]杨欣悦,王晨光,苏冠方.Coats病的诊断与治疗进展[J].眼科新进展,2017,37(2):196.[doi:10.13389/j.cnki.rao.2017.0051]
　YANG Xin-Yue,WANG Chen-Guang,SU Guan-Fang.Recent advances in diagnosis and treatment of Coats disease[J].Recent Advances in Ophthalmology,2017,37(6):196.[doi:10.13389/j.cnki.rao.2017.0051]
[8]李娟娟,HUI Shao.Exosome在眼底疾病中的研究新进展[J].眼科新进展,2018,38(2):197.[doi:10.13389/j.cnki.rao.2018.0045]
　LI Juan-Juan,HUI Shao.Research progress of exosome in ocular fundus diseases[J].Recent Advances in Ophthalmology,2018,38(6):197.[doi:10.13389/j.cnki.rao.2018.0045]
[9]张宁,张文强,丁琴,等.青光眼术后滤过泡侵犯角膜17例临床病例分析[J].眼科新进展,2018,38(4):364.[doi:10.13389/j.cnki.rao.2018.0085]
　ZHANG Ning,ZHANG Wen-Qiang,DING Qin,et al.Clinical analysis of 17 patients with corneal invasion of filtering blebafter anti-glaucomatous filtering surgery[J].Recent Advances in Ophthalmology,2018,38(6):364.[doi:10.13389/j.cnki.rao.2018.0085]
[10]邵毅.青光眼诊断与治疗规范——2017年英国专家共识解读[J].眼科新进展,2018,38(11):1001.[doi:10.13389/j.cnki.rao.2018.0236]
　SHAO Yi.Standardized glaucoma treatment:Interpretation of 2017 diagnostic and management guidelines of glaucoma by the British National Institute for Health and Care Excellence(NICE)[J].Recent Advances in Ophthalmology,2018,38(6):1001.[doi:10.13389/j.cnki.rao.2018.0236]

更新日期/Last Update: 2017-06-28